Share this article on:

00005768-201204000-0000200005768_2012_44_569_swift_different_4article< 104_0_23_4 >Medicine & Science in Sports & Exercise©2012The American College of Sports MedicineVolume 44(4)April 2012p 569–574Effect of Different Doses of Aerobic Exercise Training on Total Bilirubin Levels[CLINICAL SCIENCES]SWIFT, DAMON L.1; JOHANNSEN, NEIL M.1; EARNEST, CONRAD P.2; BLAIR, STEVEN N.3; CHURCH, TIMOTHY S.11Department of Preventive Medicine, Pennington Biomedical Research Center, Baton Rouge, LA; 2Department of Exercise Biology, Pennington Biomedical Research Center, Baton Rouge, LA; and 3Department of Exercise Science and Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SCAddress for correspondence: Damon L. Swift, Ph.D., 6400 Perkins Rd., Baton Rouge, LA 70808; E-mail: Damon.Swift@pbrc.edu.Submitted for publication May 2011.Accepted for publication August 2011.ABSTRACTLow serum bilirubin levels have been associated with increased risk for cardiovascular disease, and recent data suggest that lower body fat and reductions in weight are associated with higher bilirubin levels. However, it is unknown if exercise training can increase bilirubin levels and whether a higher dose of exercise will further increase bilirubin levels compared with a lower dose.Purpose: The primary aim of our current report was to examine whether exercise dose affects bilirubin levels in obese postmenopausal women from the Dose–Response to Exercise in Women trial. In addition, we evaluated whether changes in fitness, insulin sensitivity, and waist circumference associated with exercise training were associated with change in bilirubin levels.Methods: Participants (n = 419) were randomized to the control group or to 4, 8, and 12 kcal·kg−1·wk−1 (KKW) of exercise training at an intensity of 50% of aerobic capacity. Total bilirubin levels were evaluated at baseline and at follow-up.Results: Exercise training significantly increased serum bilirubin levels only in the 12-KKW group (0.044 mg·dL−1, P = 0.026) compared with the control group (0.004 mg·dL−1). Subgroup analyses showed that there was a significant increase in bilirubin levels in participants in the 12-KKW group (0.076 mg·dL−1) who were classified as insulin resistant (homeostatic model assessment for insulin resistance score > 2.6) compared with insulin-resistant control participants (0.018 mg·dL−1, P = 0.028).Conclusions: Our findings suggest that high doses of exercise training are necessary to significantly increase bilirubin levels in previously sedentary postmenopausal women and especially those with impaired glucose metabolism.Low serum total bilirubin concentrations are associated with increased risk of cardiovascular disease (CVD) (9,18,26), metabolic syndrome (11), and type 2 diabetes (12). Conversely, mild hyperbilirubinemia within the reference clinical range has been associated with reduced risk (9,11,12,18,26). Bilirubin modulates CVD risk by reducing lipid peroxidation and decreasing inflammation and may be a reflection of heme-oxygenase activity (10). Therefore, an increase in bilirubin levels should have clinical implications in postmenopausal women who present with elevated CVD risk (14). There is evidence that lower body fat (8) and reductions in weight (3) are associated with elevated bilirubin levels. Because aerobic exercise training has beneficial effects on body composition, it is plausible that aerobic exercise training can increase total bilirubin levels.To our knowledge, there is only one published report examining the effect of aerobic exercise training on serum bilirubin levels. Devries et al. (8) found that there was no significant change in total bilirubin level after 3 months of cycling training in lean (men = −0.4 mmol·L−1, women = 0.3 mmol·L−1) and obese men and women (men = 1.3 mmol·L−1, women = −0.5 mmol·L−1) but did note a significant inverse correlation between body fat and bilirubin level before and after training (r = −0.374, P = 0.005). However, because one standardized dose of exercise was evaluated in this study, it is unknown if there is a threshold dose of exercise necessary to significantly increase bilirubin levels. In addition, because there was a relatively small sample size (n = 29), this may have limited their ability to detect a significant change in bilirubin levels after exercise training. The primary objective of the Dose–Response to Exercise in Women (DREW) trial was to evaluate exercise levels 50% below and 50% above public health recommendations to assess whether a lower dose provides any clinical benefit and whether the higher dose provides proportionally greater clinical benefit than the standard recommended exercise level (20). Thus, the purpose of this secondary analysis was to evaluate the effect of three standardized doses of aerobic exercise training at 50% of V˙O2peak on serum bilirubin levels in overweight and obese postmenopausal women from the DREW trial. In addition, we evaluated the effect of exercise training–related changes in weight, waist circumference, fitness, and insulin resistance on serum bilirubin levels.METHODSStudy design and participants.The full design and method for the DREW trial have been published previously (20). In brief, the study was a randomized controlled trial evaluating the dose response of aerobic exercise training with increasingly higher doses of energy expenditure in 464 sedentary postmenopausal women age 45–75 yr with elevated blood pressure. The research protocol was reviewed and approved annually by the Cooper Institute institutional review board and, subsequently, approved by Pennington Biomedical Research Center for continued analysis. Written informed consent was obtained from all participants before screening. Women recruited for this study were healthy, postmenopausal, overweight or obese (body mass index (BMI) = 25.0–43.0 kg·m−2), sedentary (no participation in >20 min of exercise three times a week), elevated systolic blood pressure (120–159.0 mm Hg), and physically capable of participating in an exercise program. Exclusion criteria included the presence of CVD, significant medical conditions, elevated LDL (≥3.36 mmol·L−1), or weight loss of >9.1 kg in the previous year (20). From this population, a subset of 419 participants had available total serum bilirubin levels at baseline and follow-up.Fitness testing.Testing was performed using a Lode Excalibur Sport rate-independent cycle ergometer (Groningen, The Netherlands). Participants cycled at 30 W for 2 min, 50 W for 4 min, followed by increases of 20 W every 2 min until they could no longer maintain a pedal cadence of 50 revolutions per minute. Respiratory gases were measured using a Parvomedics Truemax 2400 Metabolic Measurement Cart (Sandy, UT). Volume and gas calibrations were conducted before each test. Gas exchange variables (V˙O2, V˙CO2 production, minute ventilation, and RER) were collected breath-by-breath and averaged into 15-s intervals. Two fitness tests were performed on separate days at baseline, and two fitness tests were performed at follow-up. The V˙O2peak values presented are the average obtained at baseline (baseline fitness tests 1 and 2) and at follow-up (follow-up fitness tests 1 and 2).Weight and waist circumference.Weight was measured on an electronic scale (Siemens Medical Solutions, Malvern, PA), which was calibrated on a weekly basis. Waist circumference was obtained using the recommendations of the Airlie Conference (17).Total serum bilirubin measurements.Total serum bilirubin was measured at baseline and follow-up in the fasting state (20) and was analyzed using a Dimension Vista 1500 Intelligent Lab System (Siemens Healthcare Diagnostics, Deerfield, IL). Samples were obtained in the morning at approximately the same time of day at baseline and follow-up and were analyzed within 24 h.Glucose, insulin, and calculation of the homeostasis model.During the baseline and the follow-up visit, we collected standard fasting (12 h) blood chemistries inclusive of insulin and glucose. In addition, we also calculated the homeostatic model assessment for insulin resistance (HOMA) as a surrogate marker of impaired glucose metabolism ([glucose × insulin] / 22.5) (19).Participant randomization.After completion of all baseline testing, participants were randomized as described previously to the 4-, 8-, or 12-kcal·kg−1·wk−1 (KKW) groups or to the nonexercise control group (20). There were a total of 419 participants in the analysis with 94, 142, 89, and 94 randomized to the control and 4-, 8-, and 12-KKW groups, respectively. The overrecruitment of the 4-KKW group in the DREW trial was decided a priori to increase power because of the smaller anticipated changes in the 4-KKW group (20).Exercise training.We calculated the exercise energy expenditure for women in the DREW age range associated with meeting the consensus public health recommendations (21) as previously reported (20). Details of these calculations are presented in the DREW design and methods report (20). Exercising women participated in three or four training sessions each week for 6 months with training intensity at the HR associated with 50% of each woman’s V˙O2peak. During the first week, each group expended 4 KKW. Those assigned to that treatment arm (4-KKW group) continued to expend 4 KKW for 6 months. All the other groups increased their energy expenditure by 1 KKW until they reached the energy expenditure required for their group. All exercise sessions were performed under the supervision of the exercise laboratory staff with complete and strict monitoring of the amount of exercise completed in each session. Participants were weighed each week, and their weight was multiplied by their exercise dosage to determine the number of calories to be expended for the week. Women in the exercise groups alternated training sessions on semirecumbent cycle ergometers and treadmills. Adherence to exercise training during the entire 6-month period was calculated for each individual by dividing the kilocalories expended during the exercise training by the kilocalories prescribed for the training period × 100%. There was excellent adherence in the DREW study, and this secondary analysis had similar compliance to the parent study (98% of the target 6-month caloric expenditure) (7). A full report of training-related data (exercise duration, kilocalories expended per week, METs per week, and sessions per week) has been previously reported in our main outcomes article (7).Women in the nonexercise control group were asked to maintain their level of activity during the 6-month study period.Blinding.There were separate intervention and assessment teams, and assessment staff members were blinded to the randomization of study participants. In addition, the exercise testing core and exercise training laboratories were on separate floors of the building. Participants were reminded regularly not to discuss their randomization with assessment team members.Statistical procedure.All statistical analyses were conducted using SAS version 9.1 (Cary, NC). Descriptive data were tabulated as means ± SD. A one-way ANOVA was performed to evaluate for significant differences of continuous baseline measurements. A χ2 test was used to test for differences in hormone therapy (HT) between groups. Changes in bilirubin, fitness, waist circumference, and weight in response to exercise training were analyzed using an ANCOVA and were adjusted for age, baseline value, and ethnicity. Results are presented as adjusted least-squares means with 95% confidence intervals (CI). HT was included as a covariate in the primary analysis to explore if it affected the change in bilirubin after exercise training. Spearman correlation coefficients were used to evaluate the relationship between baseline bilirubin and baseline weight, waist circumference, and HOMA score. In addition, we evaluated the change in bilirubin in tertiles of changes in HOMA, fitness, weight, and waist circumference after exercise training in exercisers (n = 325). A trend analysis was conducted using multiple linear regression. For confirmation, the same analysis was performed in all participants (n = 419). For all analyses, P < 0.05 was used to reject the null hypothesis.Due to the fact that lower bilirubin levels have been associated with conditions associated with impaired glucose metabolism (11–13,15) and CVD (9,18,26), we evaluated the effect of aerobic exercise training on bilirubin levels in participants who were classified as insulin resistant (HOMA score >2.6) (n = 176) and insulin sensitive at baseline (HOMA score <2.6) (n = 243). The criteria for insulin resistance were based on previous data in the literature (4). In the insulin-sensitive subgroup, there were 57, 81, 52, and 53 in the control and 4-, 8-, and 12-KKW groups, respectively. Similarly, in the insulin-resistant group, there were 37, 61, 37, and 41 in the control and 4-, 8-, and 12-KKW groups, respectively. A 2 × 4 ANCOVA was performed to test for significant differences in the change in bilirubin levels after exercise training. Multiple linear regression was performed to analyze the trend for the change in bilirubin across exercise dose in participants who were classified as insulin resistant and insulin sensitive.RESULTSDemographic data are presented in Table 1. The study sample had a mean ± SD age of 57.3 ± 6.4 yr, a mean weight of 84.3 ± 11.8 kg, a mean BMI of 32.0 ± 5.1 kg·m−2, and approximately 64% were Caucasian. The mean total bilirubin was 0.39 mg·dL−1 at baseline. There were no significant differences in baseline characteristics across groups. Similarly, whether participants were on HT between groups was not different between groups at baseline (P = 0.445). Baseline bilirubin was significantly associated with baseline fasting glucose (r = −0.13, P = 0.008), insulin (r = −0.13, P = 0.013), and HOMA score (r = −0.14, P = 0.007) but was not associated with fitness (r = 0.00, P = 0.930), BMI (r = −0.06, P = 0.236), or waist circumference (r = −0.07, P = 0.135).TABLE 1 Baseline participant characteristics.Effect of exercise training on fitness.Participants were sedentary and had low fitness with a mean V˙O2peak of 15.5 ± 2.9 mL·kg−1·min−1. Similar to the main outcomes article (7), there was a significant increase in V˙O2peak in the 4-KKW (0.51 mL·kg−1·min−1, CI = 0.17–0.85), 8-KKW (1.1 mL·kg−1·min−1, CI = 0.67–1.5), and 12-KKW (1.3 mL·kg−1·min−1, CI = 0.93–1.8) groups compared with the control (−0.35 mL·kg−1·min−1, CI = 0.93–1.77). In addition, there was a significant difference in fitness between each group with the exception of the 8- and 12-KKW groups (P = 0.276). Waist circumference was significantly reduced in the 4-KKW (−3.1 cm, CI = −4.5 to −1.7), 8-KKW (−2.7 cm, CI = −4.3 to −1.1), and 12-KKW (−3.0 cm, CI = −4.7 to −1.3) groups compared with the control (0.4 cm, CI = −1.2 to 2.0). There was no significant change in weight in the 4-KKW (−1.2 kg, CI = −1.8 to −0.5), 8-KKW (−1.7 kg, CI = −2.5 to −0.9), and 12-KKW (−1.2 kg, CI = −2.0 to −0.37) groups compared with control (−1.0 kg, CI = −1.8 to −0.2).Effect of exercise training on bilirubin.As shown in Figure 1, there was an increase in total bilirubin levels in the 12-KKW group (0.044 mg·dL−1, CI = 0.01–0.08) compared with the control (0.004 mg·dL−1, CI = −0.02 to 0.03) but not in the 4-KKW (0.025 mg·dL−1, CI = 0.00–0.05) and 8-KKW (0.020 mg·dL−1, CI = 0.01–0.08) groups. HT status at baseline did not affect the change in bilirubin with exercise, as it was not significant (P = 0.713) when it was included as a covariate in the main analysis.FIGURE 1. The effect of different doses of aerobic exercise training on total serum bilirubin levels. Shown are the effects of exercise training on total serum bilirubin levels in 419 participants from the DREW trial. Analysis was adjusted for baseline value, ethnicity, and age. Results are presented as adjusted least square means with 95% CI.Tertiles of fitness, HOMA, and waist circumference on bilirubin levels.Results of trend analyses among tertiles of change in weight, waist circumference, and HOMA scores after exercise training are shown in Table 2. There were significant trends observed for baseline HOMA score (Ptrend = 0.018) and change in HOMA score (Ptrend = 0.002) with change in total bilirubin after exercise training. There were no significant trends observed for change in bilirubin across tertiles of change in fitness, waist circumference, or weight after exercise training (Ptrend > 0.05). Similar results were observed when all participants (n = 419) were included in the analysis (data not shown).TABLE 2 Changes in serum bilirubin based on tertiles of fitness, weight, waist circumference, and insulin resistance.Effect of insulin resistance on change in serum total bilirubin.Baseline bilirubin levels were not significantly different between participants who were classified as insulin sensitive (0.41 mg·dL−1) compared with those classified as insulin resistant (0.39 mg·dL−1; P = 0.104). As shown in Figure 2, individuals classified as insulin sensitive had no significant increase in bilirubin level after exercise training at any dose of exercise compared with control participants who were classified as insulin sensitive (all P values > 0.05). However, there was a significant increase in bilirubin in individuals classified as insulin resistant in the 12-KKW (0.076 mg·dL−1) group compared with the control participants classified as insulin resistant (P = 0.028). In addition, this change was significantly greater than that in insulin-sensitive participants in the 12-KKW group (0.018 mg·dL−1, P < 0.03). The interaction term was not significant (P = 0.418). In addition, there was a significant trend observed for the change in bilirubin in individuals classified as insulin resistant (Ptrend = 0.040) but not for participants classified as insulin sensitive (Ptrend = 0.556).FIGURE 2. The effect of different doses of exercise on total serum bilirubin levels in insulin-sensitive versus insulin-resistant participants. Shown are the effects of exercise training on serum bilirubin levels in participants classified as insulin resistant (HOMA score > 2.6) (n = 176) and insulin sensitive at baseline (HOMA score < 2.6) (n = 276). Analysis was adjusted for baseline value, ethnicity, and age. Results are presented as adjusted least square means with 95% CI.DISCUSSIONThe novel finding of this investigation is that the highest dose of exercise training (12 KKW) resulted in a modest but significant elevation in serum bilirubin levels in previously sedentary postmenopausal women. Furthermore, the increase in bilirubin was greater in participants classified as insulin resistant at baseline at the highest dose of exercise compared with insulin-sensitive individuals. The mean baseline bilirubin level of our study population was low (0.39 mg·dL−1) and likely associated with elevated risk because previous data suggest that a bilirubin level below 0.7–0.8 mg·L−1 corresponds to the greatest risk of CVD (9) and diabetes (12). The findings may have important clinical implications because low serum bilirubin levels have been associated with elevated CVD risk (9,18,26).Based on previous epidemiological data, the elevation in bilirubin in the 12-KKW group in the present study (0.044 mg·dL−1) is associated with approximately a 2.6% decreased risk of peripheral vascular disease (24), a 4.0% reduced risk of stroke (25), and a 4.9% decreased risk of CVD (23). However, exercise training increased bilirubin levels almost twofold in individuals classified as insulin resistant at baseline at the highest dose of exercise (0.076 mg·dL−1, 20% change from baseline). Similarly, when change in HOMA was divided into tertiles, we observed a significant trend with reduced HOMA score and higher baseline bilirubin levels. This may have clinical implications because reduced serum bilirubin levels have been associated with insulin-resistant states such as metabolic syndrome (13) and type 2 diabetes (12), which tend to be more prevalent in postmenopausal women (6,28). There were lower baseline bilirubin levels, which approached significance in individuals who were classified as insulin resistant compared with insulin-sensitive individuals. In addition, we found a significant correlation between baseline HOMA score and baseline bilirubin levels. Therefore, we speculate that the larger magnitude of improvement after exercise training could reflect a normalization of bilirubin levels.In contrast to previous data (8), we observed no significant associations between body composition measures and bilirubin (baseline or change after exercise training). Devries et al. (8) found that body fat was inversely correlated with bilirubin before and after training. Differences between studies may be due to a smaller range in body composition because we recruited overweight and obese women, whereas Devries et al. (8) included both obese and lean participants. However, our results support Andersson et al. (3), who found that, in obese and overweight individuals undergoing sibutramine treatment, the relationship between weight loss and elevation in bilirubin levels did not become significant until participants lost more than 2% of their total body weight (3). The average amount of weight loss in the 12-KKW group was −1.4 kg (1.6% of total body weight); therefore, it may require larger amounts of overall weight loss to significantly increase bilirubin levels. In addition, Andersson et al. (3) found that changes in fasting glucose and reductions in insulin medication usage were significantly associated with higher bilirubin levels in women (3). This supports our findings that exercise-related increases in bilirubin levels observed in the present study are associated with improved glucose metabolism.Although we did not examine specific mechanisms responsible for the elevation in bilirubin with exercise training, evidence suggests that insulin-resistant states may impair heme-oxygnase-1 activity (HO-1) (1,5) (the rate-limiting enzyme responsible for the conversion of biliverin to bilirubin), and induction of HO-1 has been shown to increase insulin sensitivity in animal studies (16,22). Because exercise training may increase the activity of HO-1 system (2), it is possible that this could lead to an increase in bilirubin production. Another plausible mechanism is elevated heme catabolism via exercise-induced hemolysis because of increased heel strike, elevated core temperature, and oxidative stress during aerobic training (27). Because heme is the precursor to bilirubin production (10), greater heme bioavailability may promote elevated bilirubin levels downstream. Moreover, women in the highest dose of exercise (12-KKW group) had the greatest exposure to factors associated with exercise-induced hemolysis. However, we saw no significant changes in hemoglobin or hematocrit after exercise training (data not shown). Thus, the specific mechanisms responsible for the elevation in bilirubin levels with aerobic exercise training require further study and cannot be determined from the present investigation.The strengths of the present investigation are that DREW is a randomized controlled study with a large study population and strict monitoring of exercise training dose. An important limitation is that we measured total bilirubin; therefore, we cannot determine whether there were elevations in free, conjugated, or unconjugated bilirubin. However, much of the epidemiological data associating low bilirubin levels with cardiovascular risk are based on total bilirubin levels and not on its components (9,11,12,18,26). Another limitation of the present study is that women in DREW exercised at 50% of V˙O2peak; therefore, other exercise intensities may produce different results. Lastly, because HOMA-IR is a surrogate measure of insulin resistance, future research should investigate if similar relationships with bilirubin are found when the classification of insulin resistance is based on the results of a hyperinsulinemic euglycemic clamp.In conclusion, the results of the present study found that only the highest dose of exercise training (150% of recommended levels) significantly increased bilirubin levels in overweight and obese postmenopausal women. In addition, within the 12-KKW group, the increase in bilirubin was significantly greater in participants classified as insulin resistant at baseline compared with insulin-sensitive individuals. Our results suggest that individuals who have insulin resistance may have greater elevations in total bilirubin with high-dose exercise training compared with individuals with normal glucose tolerance. In addition, our results have public health implications because they suggests that a high dose of exercise training may have a greater impact on the reduction of cardiovascular risk compared with low-dose exercise training because of an increase in antioxidant capacity (via an elevation in bilirubin levels) along with a larger increase in cardiorespiratory fitness (7). Future studies should evaluate the effect of exercise training on bilirubin levels in individuals with greater insulin resistance (i.e., type 2 diabetes) and the specific mechanisms responsible for the increase in bilirubin with exercise training.This work was supported by National Institutes of Health (grant HL66262) and by an unrestricted research support grant from Coca-Cola.This work was performed at The Cooper Institute, and the staff is especially commended for their efforts.The authors thank the Cooper Institute Scientific Advisory Board and the DREW participants.The authors also thank the National Institutes of Health T-32 postdoctoral fellowship (Obesity: From Genes to Man) awarded to Pennington Biomedical Research Center.The authors of the present work have no conflict of interest to declare.The results of the present study do not constitute an endorsement by the American College of Sports Medicine.REFERENCES1. Abraham NG. Heme oxygenase: a target gene for anti-diabetic and obesity. Curr Pharm Des. 2008; 14: 412–21. [CrossRef] [Medline Link] [Context Link]2. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev. 2008; 60 (1): 79–127. [CrossRef] [Medline Link] [Context Link]3. Andersson C, Weeke P, Fosbøl EL, et al.. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism. 2009; 58 (8): 1109–15. [Context Link]4. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subiects with normal glucose metabolism. Diabetes Care. 2003; 26 (12): 3320–5. [CrossRef] [Full Text] [Medline Link] [Context Link]5. Bruce CR, Carey AL, Hawley JA, Febbraio MA. Intramuscular heat shock protein 72 and heme oxygenase-1 mRNA are reduced in patients with type 2 diabetes. Diabetes. 2003; 52 (9): 2338–45. [CrossRef] [Full Text] [Medline Link] [Context Link]6. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003; 88 (6): 2404–11. [Context Link]7. Church TS, Earnest CP, Skinner JS, Blair SN. Effects of different doses of physical activity on cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women with elevated blood pressure. JAMA. 2007; 297 (19): 2081–91. [CrossRef] [Full Text] [Medline Link] [Context Link]8. Devries MC, Samjoo IA, Hamadeh MJ, Tarnopolsky MA. Effect of endurance exercise on hepatic lipid content, enzymes, and adiposity in men and women. Obesity. 2008; 16 (10): 2281–8. [Medline Link] [Context Link]9. Djoussé L, Levy D, Cupples LA, Evans JC, D’Agostino RB, Ellison RC. Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol. 2001; 87 (10): 1196–200. [CrossRef] [Full Text] [Medline Link] [Context Link]10. Franchini M, Targher G, Lippi G. Serum bilirubin levels and cardiovascular disease risk: a janus bifrons? In: Advances in Clinical Chemistry. Vol. 50. San Diego (CA): Elsevier Academic Press, Inc.; 2010. p. 47–63. [Context Link]11. Giral P, Ratziu V, Couvert P, et al.. Plasma bilirubin and γ-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. Atherosclerosis. 2010; 210 (2): 607–13. [Context Link]12. Han SS, Na KY, Chae DW, Kim YS, Kim S, Chin HJ. High serum bilirubin is associated with the reduced risk of diabetes mellitus and diabetic nephropathy. Tohoku J Exp Med. 2010; 221 (2): 133–40. [CrossRef] [Medline Link] [Context Link]13. Hwang HJ, Kim SH. Inverse relationship between fasting direct bilirubin and metabolic syndrome in Korean adults. Clin Chim Acta. 2010; 411 (19–20): 1496–501. [CrossRef] [Medline Link] [Context Link]14. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease. Ann Intern Med. 1976; 85 (4): 447–52. [Context Link]15. Kim SH, Lee JW, Im JA, Hwang HJ. Increased γ-glutamyltransferase and decreased total bilirubin are associated with metabolic syndrome in Korean postmenopausal women. Clin Chem Lab Med. 2010; 48 (11): 1623–8. [CrossRef] [Full Text] [Medline Link] [Context Link]16. Li M, Kim DH, Tsenovoy PL, et al.. Treatment of obese diabetic mice with a heme oxygenase inducer reduces visceral and subcutaneous adiposity, increases adiponectin levels, and improves insulin sensitivity and glucose tolerance. Diabetes. 2008; 57 (6): 1526–35. [Context Link]17. Lohman T. Antropometric Standardization Reference Manual. Champaign (IL): Human Kinetics; 1988. p. 44–6. [Context Link]18. Madhavan M, Wattigney WA, Srinivasan SR, Berenson GS. Serum bilirubin distribution and its relation to cardiovascular risk in children and young adults. Atherosclerosis. 1997; 131 (1): 107–13. [CrossRef] [Medline Link] [Context Link]19. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28 (7): 412–9. [CrossRef] [Medline Link] [Context Link]20. Morss GM, Jordan AN, Skinner JS, et al.. Dose–response to exercise in women aged 45–75 yr (DREW): design and rationale. Med Sci Sports Exerc. 2004; 36 (2): 336–44. [Context Link]21. National Institute of Health. Physical activity and cardiovascular health: NIH consensus development panel on physical activity and cardiovascular health. JAMA. 1996; 276 (3): 241–6. [CrossRef] [Full Text] [Medline Link] [Context Link]22. Ndisang JF, Lane N, Syed N, Jadhav A. Up-regulating the heme oxygenase system with hemin improves insulin sensitivity and glucose metabolism in adult spontaneously hypertensive rats. Endocrinology. 2010; 151 (2): 549–60. [CrossRef] [Full Text] [Medline Link] [Context Link]23. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med. 2003; 228 (5): 568–71. [Medline Link] [Context Link]24. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol. 2008; 28 (1): 166–72. [Context Link]25. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999–2004. Am J Med. 2008; 121 (9): 781–8.e1. [Context Link]26. Schwertner H, Jackson W, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem. 1994; 40 (1): 18–23. [Medline Link] [Context Link]27. Sentürk ÜK, Gündüz F, Kuru O, et al.. Exercise-induced oxidative stress leads hemolysis in sedentary but not trained humans. J Appl Physiol. 2005; 99 (4): 1434–41. [Context Link]28. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med. 1998; 158 (6): 617–21. [CrossRef] [Full Text] [Medline Link] [Context Link] ANTIOXIDANT CAPACITY; PHYSICAL ACTIVITY; DOSE–RESPONSE; POSTMENOPAUSALovid.com:/bib/ovftdb/00005768-201204000-0000200120515_2008_14_412_abraham_oxygenase_|00005768-201204000-00002#xpointer(id(R1-2))|11065213||ovftdb|SL0012051520081441211065213P70[CrossRef]10.2174%2F138161208783597371ovid.com:/bib/ovftdb/00005768-201204000-0000200120515_2008_14_412_abraham_oxygenase_|00005768-201204000-00002#xpointer(id(R1-2))|11065405||ovftdb|SL0012051520081441211065405P70[Medline Link]18289068ovid.com:/bib/ovftdb/00005768-201204000-0000200006492_2008_60_79_abraham_pharmacological_|00005768-201204000-00002#xpointer(id(R2-2))|11065213||ovftdb|SL000064922008607911065213P71[CrossRef]10.1124%2Fpr.107.07104ovid.com:/bib/ovftdb/00005768-201204000-0000200006492_2008_60_79_abraham_pharmacological_|00005768-201204000-00002#xpointer(id(R2-2))|11065405||ovftdb|SL000064922008607911065405P71[Medline Link]18323402ovid.com:/bib/ovftdb/00005768-201204000-0000200003458_2003_26_3320_ascaso_quantitative_|00005768-201204000-00002#xpointer(id(R4-2))|11065213||ovftdb|00003458-200312000-00019SL00003458200326332011065213P73[CrossRef]10.2337%2Fdiacare.26.12.3320ovid.com:/bib/ovftdb/00005768-201204000-0000200003458_2003_26_3320_ascaso_quantitative_|00005768-201204000-00002#xpointer(id(R4-2))|11065404||ovftdb|00003458-200312000-00019SL00003458200326332011065404P73[Full Text]00003458-200312000-00019ovid.com:/bib/ovftdb/00005768-201204000-0000200003458_2003_26_3320_ascaso_quantitative_|00005768-201204000-00002#xpointer(id(R4-2))|11065405||ovftdb|00003458-200312000-00019SL00003458200326332011065405P73[Medline Link]14633821ovid.com:/bib/ovftdb/00005768-201204000-0000200003439_2003_52_2338_bruce_intramuscular_|00005768-201204000-00002#xpointer(id(R5-2))|11065213||ovftdb|00003439-200309000-00019SL00003439200352233811065213P74[CrossRef]10.2337%2Fdiabetes.52.9.2338ovid.com:/bib/ovftdb/00005768-201204000-0000200003439_2003_52_2338_bruce_intramuscular_|00005768-201204000-00002#xpointer(id(R5-2))|11065404||ovftdb|00003439-200309000-00019SL00003439200352233811065404P74[Full Text]00003439-200309000-00019ovid.com:/bib/ovftdb/00005768-201204000-0000200003439_2003_52_2338_bruce_intramuscular_|00005768-201204000-00002#xpointer(id(R5-2))|11065405||ovftdb|00003439-200309000-00019SL00003439200352233811065405P74[Medline Link]12941774ovid.com:/bib/ovftdb/00005768-201204000-0000200005407_2007_297_2081_church_cardiorespiratory_|00005768-201204000-00002#xpointer(id(R7-2))|11065213||ovftdb|00005407-200705160-00024SL000054072007297208111065213P76[CrossRef]10.1001%2Fjama.297.19.2081ovid.com:/bib/ovftdb/00005768-201204000-0000200005407_2007_297_2081_church_cardiorespiratory_|00005768-201204000-00002#xpointer(id(R7-2))|11065404||ovftdb|00005407-200705160-00024SL000054072007297208111065404P76[Full Text]00005407-200705160-00024ovid.com:/bib/ovftdb/00005768-201204000-0000200005407_2007_297_2081_church_cardiorespiratory_|00005768-201204000-00002#xpointer(id(R7-2))|11065405||ovftdb|00005407-200705160-00024SL000054072007297208111065405P76[Medline Link]17507344ovid.com:/bib/ovftdb/00005768-201204000-0000200072240_2008_16_2281_devries_endurance_|00005768-201204000-00002#xpointer(id(R8-2))|11065405||ovftdb|SL00072240200816228111065405P77[Medline Link]ovid.com:/bib/ovftdb/00005768-201204000-0000200000416_2001_87_1196_djousse_cardiovascular_|00005768-201204000-00002#xpointer(id(R9-2))|11065213||ovftdb|00000416-200105150-00013SL00000416200187119611065213P78[CrossRef]10.1016%2FS0002-9149%2801%2901494-1ovid.com:/bib/ovftdb/00005768-201204000-0000200000416_2001_87_1196_djousse_cardiovascular_|00005768-201204000-00002#xpointer(id(R9-2))|11065404||ovftdb|00000416-200105150-00013SL00000416200187119611065404P78[Full Text]00000416-200105150-00013ovid.com:/bib/ovftdb/00005768-201204000-0000200000416_2001_87_1196_djousse_cardiovascular_|00005768-201204000-00002#xpointer(id(R9-2))|11065405||ovftdb|00000416-200105150-00013SL00000416200187119611065405P78[Medline Link]11356398ovid.com:/bib/ovftdb/00005768-201204000-0000200007811_2010_221_133_han_nephropathy_|00005768-201204000-00002#xpointer(id(R12-2))|11065213||ovftdb|SL00007811201022113311065213P81[CrossRef]10.1620%2Ftjem.221.133ovid.com:/bib/ovftdb/00005768-201204000-0000200007811_2010_221_133_han_nephropathy_|00005768-201204000-00002#xpointer(id(R12-2))|11065405||ovftdb|SL00007811201022113311065405P81[Medline Link]20495302ovid.com:/bib/ovftdb/00005768-201204000-0000200003031_2010_411_1496_hwang_relationship_|00005768-201204000-00002#xpointer(id(R13-2))|11065213||ovftdb|SL000030312010411149611065213P82[CrossRef]10.1016%2Fj.cca.2010.06.003ovid.com:/bib/ovftdb/00005768-201204000-0000200003031_2010_411_1496_hwang_relationship_|00005768-201204000-00002#xpointer(id(R13-2))|11065405||ovftdb|SL000030312010411149611065405P82[Medline Link]ovid.com:/bib/ovftdb/00005768-201204000-0000200115728_2010_48_1623_kim_glutamyltransferase_|00005768-201204000-00002#xpointer(id(R15-2))|11065213||ovftdb|00115728-201011000-00012SL00115728201048162311065213P84[CrossRef]10.1515%2Fcclm.2010.302ovid.com:/bib/ovftdb/00005768-201204000-0000200115728_2010_48_1623_kim_glutamyltransferase_|00005768-201204000-00002#xpointer(id(R15-2))|11065404||ovftdb|00115728-201011000-00012SL00115728201048162311065404P84[Full Text]00115728-201011000-00012ovid.com:/bib/ovftdb/00005768-201204000-0000200115728_2010_48_1623_kim_glutamyltransferase_|00005768-201204000-00002#xpointer(id(R15-2))|11065405||ovftdb|00115728-201011000-00012SL00115728201048162311065405P84[Medline Link]20704533ovid.com:/bib/ovftdb/00005768-201204000-0000200000898_1997_131_107_madhavan_cardiovascular_|00005768-201204000-00002#xpointer(id(R18-2))|11065213||ovftdb|SL00000898199713110711065213P87[CrossRef]10.1016%2FS0021-9150%2897%2906088-7ovid.com:/bib/ovftdb/00005768-201204000-0000200000898_1997_131_107_madhavan_cardiovascular_|00005768-201204000-00002#xpointer(id(R18-2))|11065405||ovftdb|SL00000898199713110711065405P87[Medline Link]9180251ovid.com:/bib/ovftdb/00005768-201204000-0000200003441_1985_28_412_matthews_concentrations_|00005768-201204000-00002#xpointer(id(R19-2))|11065213||ovftdb|SL0000344119852841211065213P88[CrossRef]10.1007%2FBF00280883ovid.com:/bib/ovftdb/00005768-201204000-0000200003441_1985_28_412_matthews_concentrations_|00005768-201204000-00002#xpointer(id(R19-2))|11065405||ovftdb|SL0000344119852841211065405P88[Medline Link]3899825ovid.com:/bib/ovftdb/00005768-201204000-0000200005407_1996_276_241_anonymous_cardiovascular_|00005768-201204000-00002#xpointer(id(R21-2))|11065213||ovftdb|00005407-199607170-00040SL00005407199627624111065213P90[CrossRef]10.1001%2Fjama.1996.03540030075036ovid.com:/bib/ovftdb/00005768-201204000-0000200005407_1996_276_241_anonymous_cardiovascular_|00005768-201204000-00002#xpointer(id(R21-2))|11065404||ovftdb|00005407-199607170-00040SL00005407199627624111065404P90[Full Text]00005407-199607170-00040ovid.com:/bib/ovftdb/00005768-201204000-0000200005407_1996_276_241_anonymous_cardiovascular_|00005768-201204000-00002#xpointer(id(R21-2))|11065405||ovftdb|00005407-199607170-00040SL00005407199627624111065405P90[Medline Link]8667571ovid.com:/bib/ovftdb/00005768-201204000-0000200003571_2010_151_549_ndisang_spontaneously_|00005768-201204000-00002#xpointer(id(R22-2))|11065213||ovftdb|00003571-201002000-00014SL00003571201015154911065213P91[CrossRef]10.1210%2Fen.2009-0471ovid.com:/bib/ovftdb/00005768-201204000-0000200003571_2010_151_549_ndisang_spontaneously_|00005768-201204000-00002#xpointer(id(R22-2))|11065404||ovftdb|00003571-201002000-00014SL00003571201015154911065404P91[Full Text]00003571-201002000-00014ovid.com:/bib/ovftdb/00005768-201204000-0000200003571_2010_151_549_ndisang_spontaneously_|00005768-201204000-00002#xpointer(id(R22-2))|11065405||ovftdb|00003571-201002000-00014SL00003571201015154911065405P91[Medline Link]20016031ovid.com:/bib/ovftdb/00005768-201204000-0000200003680_2003_228_568_novotny_atherosclerosis_|00005768-201204000-00002#xpointer(id(R23-2))|11065405||ovftdb|SL00003680200322856811065405P92[Medline Link]12709588ovid.com:/bib/ovftdb/00005768-201204000-0000200003030_1994_40_18_schwertner_concentration_|00005768-201204000-00002#xpointer(id(R26-2))|11065405||ovftdb|SL000030301994401811065405P95[Medline Link]8287538ovid.com:/bib/ovftdb/00005768-201204000-0000200000779_1998_158_617_sowers_cardiovascular_|00005768-201204000-00002#xpointer(id(R28-2))|11065213||ovftdb|00000779-199803230-00007SL00000779199815861711065213P97[CrossRef]10.1001%2Farchinte.158.6.617ovid.com:/bib/ovftdb/00005768-201204000-0000200000779_1998_158_617_sowers_cardiovascular_|00005768-201204000-00002#xpointer(id(R28-2))|11065404||ovftdb|00000779-199803230-00007SL00000779199815861711065404P97[Full Text]00000779-199803230-00007ovid.com:/bib/ovftdb/00005768-201204000-0000200000779_1998_158_617_sowers_cardiovascular_|00005768-201204000-00002#xpointer(id(R28-2))|11065405||ovftdb|00000779-199803230-00007SL00000779199815861711065405P97[Medline Link]9521226Effect of Different Doses of Aerobic Exercise Training on Total Bilirubin LevelsSWIFT, DAMON L.; JOHANNSEN, NEIL M.; EARNEST, CONRAD P.; BLAIR, STEVEN N.; CHURCH, TIMOTHY S.Clinical Sciences444